Company file

Identity

Eukarÿs

Eukarÿs develops synthetic gene therapies, a novel non-viral therapeutic platform. Synthetic gene therapy relies on Eukarÿs’ proprietary technologies (i.e. C3P3 – the first ever artificial system able to synthesize autonomously the messenger RNA in cells – and Möbius – an technology to produce the therapeutic synthetic DNA used for therapeutics). Synthetic gene therapy is designed to resolve the main obstacles that other approaches must face, i.e. safety, tolerance, efficacy, vectorization immunogenicity, low production costs and can be adapted to most human disorders. Eukarÿs current pipeline is for liver diseases, with the most advanced product currently at CMC before non-regulatory preclinical phase. The same technologies were recently adapted to vaccination gene vaccination, with a special focus on Covid-19/SARS-Cov-2, with the objective to develop cost-effective and potent vaccines.